Nuclear receptor corepressor (NCoR) is a positive prognosticator for cervical cancer.
Cervical cancer
Epigenetic
Immunohistochemistry
NCoR
Prognosis
Journal
Archives of gynecology and obstetrics
ISSN: 1432-0711
Titre abrégé: Arch Gynecol Obstet
Pays: Germany
ID NLM: 8710213
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
received:
17
11
2020
accepted:
27
03
2021
pubmed:
17
4
2021
medline:
26
11
2021
entrez:
16
4
2021
Statut:
ppublish
Résumé
Enzymes with epigenetic functions play an essential part in development of cancer. However, the significance of epigenetic changes in cervical carcinoma as a prognostic factor has not been fully investigated. Nuclear receptor corepressor (NCoR) presents itself as a potentially important element for epigenetic modification and as a potential prognostic aspect in cervical cancer. By immunohistochemical staining of 250 tumor samples, the expression strength of NCoR was measured and evaluated by immunoreactive score (IRS) in the nucleus and cytoplasm. A low expression of NCoR in our patients was a disadvantage in overall survival. Expression of NCoR was negatively correlated with viral oncoprotein E6, acetylated histone H3 acetyl K9 and FIGO status, and positively correlated to p53. Our study has identified epigenetic modification of tumor cells thus seems to be of relevance in cervical cancer as well for diagnosis, as a marker or as a potential therapeutic target in patients with advanced cervical carcinoma.
Identifiants
pubmed: 33861372
doi: 10.1007/s00404-021-06053-3
pii: 10.1007/s00404-021-06053-3
pmc: PMC8490237
doi:
Substances chimiques
Co-Repressor Proteins
0
Oncogene Proteins, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1307-1314Informations de copyright
© 2021. The Author(s).
Références
Histopathology. 2002 Sep;41(3):185-207
pubmed: 12207781
Cell. 1993 Nov 5;75(3):495-505
pubmed: 8221889
Oncotarget. 2017 Oct 31;8(62):105356-105371
pubmed: 29285256
Oncol Lett. 2017 Oct;14(4):4467-4476
pubmed: 29085443
Mol Oncol. 2007 Jun;1(1):19-25
pubmed: 19383284
Br J Cancer. 2017 Jan 3;116(1):50-57
pubmed: 27875522
Biochem Soc Trans. 2009 Jun;37(Pt 3):569-76
pubmed: 19442252
Anticancer Res. 2016 Jun;36(6):3195-8
pubmed: 27272848
Lancet Oncol. 2014 Mar;15(3):249-51
pubmed: 24529698
Science. 1990 Apr 6;248(4951):76-9
pubmed: 2157286
J Natl Cancer Inst. 2011 Mar 2;103(5):368-83
pubmed: 21282563
Nature. 2007 May 10;447(7141):178-82
pubmed: 17468743
Virology. 2006 Oct 25;354(2):280-5
pubmed: 16905170
Neuropharmacology. 2014 May;80:53-60
pubmed: 24440532
Cancer Res. 1998 Jan 15;58(2):362-6
pubmed: 9443418
Int J Mol Sci. 2017 Feb 23;18(3):
pubmed: 28241481
Genes Dev. 2000 Jan 1;14(1):45-54
pubmed: 10640275
APMIS. 2007 Oct;115(10):1039-59
pubmed: 18042143
Cell. 1998 May 29;93(5):705-16
pubmed: 9630216
BMC Res Notes. 2019 Jun 17;12(1):343
pubmed: 31208445
Biochem Biophys Res Commun. 2012 Jul 6;423(3):564-70
pubmed: 22695118
Viruses. 2013 May 14;5(5):1231-49
pubmed: 23673719
Nat Rev Cancer. 2014 Jun;14(6):395-405
pubmed: 24854082
Proc Natl Acad Sci U S A. 1997 Aug 19;94(17):9028-33
pubmed: 9256429
Cancer Res. 2002 Dec 1;62(23):7075-82
pubmed: 12460929
EMBO J. 2003 Mar 17;22(6):1336-46
pubmed: 12628926
Nat Rev Genet. 2010 Feb;11(2):109-23
pubmed: 20084085
Bioessays. 1998 Aug;20(8):615-26
pubmed: 9780836
J Biol Chem. 2001 May 25;276(21):18075-81
pubmed: 11278548
Clin Cancer Res. 2000 Feb;6(2):512-8
pubmed: 10690532
J Virol. 1989 Oct;63(10):4417-21
pubmed: 2476573
Science. 1989 Feb 17;243(4893):934-7
pubmed: 2537532
Cancer Cell. 2010 Nov 16;18(5):436-47
pubmed: 21075309
Obstet Gynecol Sci. 2019 May;62(3):157-165
pubmed: 31139591
Cancer Res. 2007 Apr 15;67(8):3976-85
pubmed: 17440114
Trends Pharmacol Sci. 2003 Feb;24(2):96-102
pubmed: 12559775
Cell. 2013 Mar 28;153(1):38-55
pubmed: 23540689
Am J Clin Exp Urol. 2014 Oct 02;2(3):169-87
pubmed: 25374920
Genes Dev. 2006 Dec 1;20(23):3215-31
pubmed: 17158741
Cell Res. 2007 Mar;17(3):195-211
pubmed: 17325692